<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7FD0CEE1-418F-4210-9BBA-62C1F7094A05"><gtr:id>7FD0CEE1-418F-4210-9BBA-62C1F7094A05</gtr:id><gtr:name>Allostera Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7FD0CEE1-418F-4210-9BBA-62C1F7094A05"><gtr:id>7FD0CEE1-418F-4210-9BBA-62C1F7094A05</gtr:id><gtr:name>Allostera Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3CF9EB25-5323-4160-9802-0B125921F055"><gtr:id>3CF9EB25-5323-4160-9802-0B125921F055</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>McRae</gtr:otherNames><gtr:surname>Allan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC247267-DA2E-47CD-838A-348F17241C68"><gtr:id>DC247267-DA2E-47CD-838A-348F17241C68</gtr:id><gtr:firstName>Nancy</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Rothwell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9219675"><gtr:id>A5682412-E7F4-4E9C-83C7-D064BD300F0B</gtr:id><gtr:title>IL-1 and neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9219675</gtr:grantReference><gtr:abstractText>Nancy Rothwell has given numerous lectures (including many live demonstrations) to the public and schools, on many topics in research. She is currently President of the Medical Section of the BA and an active member of the European DANA Alliance for the Brain. She has written many articles for non-scientists about her own research, research careers and particularly on the importance of animals in medical research. 

Stuart Allan has given several public lectures and has been directly involved in the supervision of school children during visits to our lab. We often host school children on work experience in our lab.

The School of Biological Sciences now holds a formal course for graduates and post docs in public engagement in science. Many members of our lab participate in these activities through visits to schools, talks and supervising visitors. We consider that these activities are extremely important and they are actively encouraged.</gtr:abstractText><gtr:technicalSummary>Our ultimate goal is to understand the mechanisms underlying neuronal death, and thus to develop novel therapeutic approaches for neurodegenerative disorders, by identifying the mechanisms of action of the cytokine interleukin-1 (IL-1).

We demonstrated that IL-1 mediates experimentally induced ischaemic, excitotoxic and traumatic brain injury. We showed that the naturally occurring IL-1 receptor antagonist (IL-1ra) is a potent neuroprotective agent, which is now in early clinical trials in stroke.
The aim of this programme is to determine how IL-1 mediates and exacerbates neuronal injury.
To do this we will address three fundamental questions, based on our recent observations:

1) How does IL-1 mediate neuronal death?
We will test the hypotheses that IL-1:
i) acts on non-neuronal cells to release (as yet unidentified) neurotoxins.
ii) primes neurones for cell death.
iii) mediates or exacerbates neuronal death in vivo through actions on local blood flow, local brain temperature and/or increased seizure activity.
In each case we will subsequently investigate the mediators and mechanisms.

2) Which receptors mediate IL-1 actions in the brain?
We will further test our hypothesis that IL-1 acts through new receptors, and identify IL-1 signalling mechanisms.

3) What is the role of newly identified members of the IL-1 family?
We will test the hypothesis that new IL-1 ligands contribute to neurodegeneration and/or interact with the known IL-1 system.
This programme combines molecular, cellular and whole animal approaches. We have extensive preliminary data, experience, and unique access to reagents. The results could lead to new treatments for neurodegenerative disorders.</gtr:technicalSummary><gtr:fund><gtr:end>2008-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1993-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3795766</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Studies of Amgen's interleukin-1 receptor antagonist (IL-1RA) in neuroprotection against cerebral ischaemia</gtr:description><gtr:id>6D03E8F5-B9AA-472D-B938-495EEAD2B6C6</gtr:id><gtr:impact>Results of preclinical studies have lead to phase II trial in stroke patients (Sir Jules Thorn Charitable Trust grant - pre-2006), pharmacokinetic study in subarachnoid haemorrhage (SAH) patients (Experimental Medicine grant G0502030 - just completed)) and phase II randomised controlled double blind trial (IL-1RA vs placebo) in SAH patients (Experimental Medicine grant G0502030 - ongoing).
Amgen has since sold the licence for IL1-RA to Swedish Orphan Biovitrum, so currently setting up a 3-way agreement with both companies for IL-1RA for further preclinical studies.
Nov. '11: 3-way agreement finalised, material received, and preclinical neuroprotection experiments ongoing.</gtr:impact><gtr:outcomeId>F8C6BF59645-1</gtr:outcomeId><gtr:partnerContribution>Provision of material for studies</gtr:partnerContribution><gtr:piContribution>Carried out in vitro and in vivo preclinical studies of IL-1RA in cerebral ischaemia, leading to phase II trials in stroke and subarachnoid haemorrhage (SAH) patients (Experimental Medicine grant G0502030).</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syngenta</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Microarray analysis and support of PhD student</gtr:description><gtr:id>A98AB673-9058-4856-991C-BD84E634AFE5</gtr:id><gtr:impact>One collaborative paper published: Tsakiri N., Kimber I., Rothwell N.J., Pinteaux E. (2008) Differential effects of IL-1a and IL-1b on IL-6 and chemokines synthesis in neurones. Mol. Cell. Neurosci. 38, 259-265. PubMed ID 18722361.</gtr:impact><gtr:outcomeId>122437E7B1E-1</gtr:outcomeId><gtr:partnerContribution>microarray analysis and support of PhD student</gtr:partnerContribution><gtr:piContribution>The PhD student funded by this CASE-studentship was fully trained and conducted all microarray analyses under the supervision of the industrial partner (Prof Ian Kimber). Specific genes of interest found on the microarray chip, were further test by our research team.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB CASE studentship</gtr:description><gtr:id>C159497B-9D96-4709-B8F2-87DAAE7E762B</gtr:id><gtr:impact>Paper published (PubMed ID 19654587) and oral presentation at international conference</gtr:impact><gtr:outcomeId>73480B3334D-1</gtr:outcomeId><gtr:partnerContribution>Provided equipment and support for multiplex analysis of samples.</gtr:partnerContribution><gtr:piContribution>Funded PhD student to investigate inflammatory responses to experimental stroke</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Allostera Pharma</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Studies of Allostera's IL-1R antagonist in neuroprotection against cerebral ischaemia</gtr:description><gtr:id>558C194B-8B1E-48A2-B4AD-D7A98C09A12E</gtr:id><gtr:impact>Results from initial studies were promising, therefore currently arranging research contract for futher studies. 

Nov. 2010 update: company closed down, therefore contract terminated.</gtr:impact><gtr:outcomeId>D6A176BB842-1</gtr:outcomeId><gtr:partnerContribution>Provision of material for studies</gtr:partnerContribution><gtr:piContribution>Performed initial studies with material to test for neuroprotection in experimental models of cerebral ischaemia.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of Amgen IL-1RA for clinical studies</gtr:description><gtr:id>79A2E7F4-31D5-4C4A-B702-B8A31D67C360</gtr:id><gtr:impact>Pharmacokinetic study identified optimal dosing regime of IL-1RA in SAH patients to take forward to test efficacy in further trials. Phase II randomised controlled double blind trial (IL-1RA vs placebo) now completed in SAH patients (analysis in progress).</gtr:impact><gtr:outcomeId>8751115D3FF-1</gtr:outcomeId><gtr:partnerContribution>Provision of IL-1RA for clinical studies</gtr:partnerContribution><gtr:piContribution>Carried out pharmacokinetic study to identify optimal dosing regime of IL-1RA in SAH patients.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Keynote lecture to Schools Science Conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F75C013E-1D44-47FA-8F19-E71DB55AFAA4</gtr:id><gtr:impact>Talk followed by Q&amp;amp;A session. Title: &amp;quot;A stroke of bad luck - new discoveries in the treatment of brain disease&amp;quot;. Session: Science is the Future.
Venue : Royal College of Pathologists, London
Audience : 50 secondary year students from years 10-13 and their teachers

No specific impact known.</gtr:impact><gtr:outcomeId>Lk5nSPG9mMS</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frontiers of Science talk, Uni of Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4BE20AC3-C583-4AA2-B3A0-4ACBA153D15E</gtr:id><gtr:impact>Frontiers of Science talk delivered to ~150 undergraduate students from 1st year to 3rd year, followed by questions and discussion. 
Title: &amp;quot;Flaming brains - new discoveries about brain disease&amp;quot;


No specific impact known.</gtr:impact><gtr:outcomeId>C55QFTfaDfg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Numerous scientific, public and policy talks - too many to detail</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>8E5E6DC7-9200-49D8-9E10-6F5C963D684F</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:outcomeId>1716FB71527</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Event for stroke patients and carers, Nov. 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>39708728-99D5-4337-8BBC-EA769AC819BA</gtr:id><gtr:impact>10 stroke survivors/carers attended an event called &amp;quot;Stroke research - from test tube to treatment&amp;quot;, which comprised talks from 3 researchers, spanning preclinical to clinical studies, and interacted with post-docs and students over various displays and refreshments. The feedback from attendees was mostly very positive and all but one expressed an interest in attending future events. The constructive feedback has made us re-evaluate what we want to achieve from such events and will inform future events.

We are re-evaluating the aims of such events and are planning further, larger events, taking into account the feedback received from this meeting. Specifically, we will be involved in a large event for World Stroke Day 2011, with our clinical colleagues.</gtr:impact><gtr:outcomeId>ehMi5Arfh5S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at the University of Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>77500C9C-7540-46F0-A3E1-AD8DAAB92EE9</gtr:id><gtr:impact>Talk title: &amp;quot;A stroke of bad luck: mechanisms and treatments for brain disease&amp;quot;. For ~200 Uni staff and students. Followed by questions and discussion.

No specific impact known.</gtr:impact><gtr:outcomeId>r8vUB86TSKs</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>All types and numerous locations; numerous examples</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>E6E8D007-D308-4E67-9166-D760BFB13F04</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:outcomeId>32113AF531B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Give approx. 10-12 public and schools lectures each year (too numerous to detail)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>24F4EEBD-A45D-4EF9-B203-98DAB3E4403D</gtr:id><gtr:impact>Give approx. 10-12 public and schools lectures each year (too numerous to detail)

Not possible to detail specific impacts - aim to increase interest in science, particularly in underprivileged areas. Often receive requests from school students wishing to do work experience in the lab, following a talk at their school (all of whom we aim to accommodate wherever possible).</gtr:impact><gtr:outcomeId>8455F4C626C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual STARS lecture, Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>041A5533-342E-4573-81BB-2AF6A061B7C9</gtr:id><gtr:impact>Annual STARS lecture to ~200 local sixth form and college students.
Title: 'A stroke of bad luck: Understanding brain disease' (targeted at A level Biology).

Not known.</gtr:impact><gtr:outcomeId>PFRnDs3rxGz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Day 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>82044C99-165D-48F6-AF2F-66EB9F4AEAAC</gtr:id><gtr:impact>World Stroke Day event in Oct. 2011 organised by our clinical colleagues. The clinical investigator Dr Tyrrell presented the results of the clinical study funded by this grant. The audience comprised ~180 stroke patients and their carers, healthcare professionals and associated charities/organisations.

Not known.</gtr:impact><gtr:outcomeId>kf5b4x2Axs7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>720000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Career Development Fellowship</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C7FC3FEA-4263-4372-A93C-AC8447DD4977</gtr:id><gtr:outcomeId>BAF17F705A10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>857000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU FP7 grant</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>C8B75701-B013-4184-AB4F-19D25B998472</gtr:id><gtr:outcomeId>CEEFC9F1C3E0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (PSMB)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0802001</gtr:fundingRef><gtr:id>774612D1-FF69-4E4E-BDD7-C6E674189057</gtr:id><gtr:outcomeId>125723014BD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>640000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Models of Disease Grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801040</gtr:fundingRef><gtr:id>1E55D721-A4D9-4F82-8442-147E47FFCEE7</gtr:id><gtr:outcomeId>188400202F00</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (NMHB)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801296</gtr:fundingRef><gtr:id>6090DC94-FBC6-4B39-8873-80AA2B355001</gtr:id><gtr:outcomeId>367AAE757CC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001252</gtr:fundingRef><gtr:id>8972F404-B99F-4F09-B3E3-6FA5BE4C5F35</gtr:id><gtr:outcomeId>Dt7ETj7QHm60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>608148</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant (Combinatorial Systems Biology of ROS-Regulated Interleukin-1 Gene Expression)</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/F018398/1</gtr:fundingRef><gtr:id>5FDE0377-F28C-4AE0-B28E-F99D48DDC00F</gtr:id><gtr:outcomeId>91D7F0527580</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>520000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Experimental Medicine Grant</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0502030</gtr:fundingRef><gtr:id>53DEC714-C601-4A40-A760-454E6501BF0B</gtr:id><gtr:outcomeId>FBA8F0CC4DB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Collaboration with Amgen Inc. to test the clinical utility of IL-1RA for stroke in man. The first clinical phase II study was completed in 2004. Patent granted initially in US in 2000; other international applications went to grant in 2002, 2003, 2004 and 2008.</gtr:description><gtr:grantRef>G9219675</gtr:grantRef><gtr:id>09CDC1C9-15A8-4E04-A7C7-74824E591E72</gtr:id><gtr:impact>The data gathered suggest that rhIL-1RA is safe and well tolerated in acute stroke. In addition, rhIL-1RA exhibited biological activity that is relevant to the pathophysiology and clinical outcome of ischaemic stroke. These data demonstrate that rhIL- 1RA has potential as a new therapeutic agent for acute stroke. A pharmacokinetic study of IL-1RA in SAH patients has just been completed(Experimental Medicine grant G0502030).</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>D708FE89D39</gtr:outcomeId><gtr:patentId>WO9308820</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>New use for IL-1RA to treat neurodegeneration</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F90FBB15-3557-467E-B648-198C1BB3A705</gtr:id><gtr:title>Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9d37cf5553ced351d10ac42672be61e"><gtr:id>f9d37cf5553ced351d10ac42672be61e</gtr:id><gtr:otherNames>Luheshi NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>7A295F5BFE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>690C2DD0-B933-4F19-9E8B-E23798C17493</gtr:id><gtr:title>Gene regulation by IL-1beta independent of IL-1R1 in the mouse brain.</gtr:title><gtr:parentPublicationTitle>Glia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0894-1491</gtr:issn><gtr:outcomeId>53A1E9F1246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0546D1C3-C68B-4FAB-8BF0-AD9103D47E1F</gtr:id><gtr:title>Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf81e6d63529589fdd81830434dc6748"><gtr:id>cf81e6d63529589fdd81830434dc6748</gtr:id><gtr:otherNames>Brough D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>7C5A3E974A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DDA3D2B-8ABE-47BD-A242-BEDC5961AAC2</gtr:id><gtr:title>Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd04252fa0d3c89e49219f4364989991"><gtr:id>cd04252fa0d3c89e49219f4364989991</gtr:id><gtr:otherNames>Molina-Holgado F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>71AF70605EC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23949FEF-2470-4110-8626-24C49C8C80EE</gtr:id><gtr:title>Radiolabeling with fluorine-18 of a protein, interleukin-1 receptor antagonist.</gtr:title><gtr:parentPublicationTitle>Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a98d9b438e9756daa2e0f77381e97869"><gtr:id>a98d9b438e9756daa2e0f77381e97869</gtr:id><gtr:otherNames>Prenant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0969-8043</gtr:issn><gtr:outcomeId>FNw1iMnbjBK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29CBE80A-80AB-4761-BC57-62D74A114C25</gtr:id><gtr:title>Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd02fd254ff5c1ab0efc233b3f8f0b5"><gtr:id>3dd02fd254ff5c1ab0efc233b3f8f0b5</gtr:id><gtr:otherNames>Thornton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>AB6E7DE8CF0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6ADBEEC-0A9D-45A9-97E7-A5E7BA942204</gtr:id><gtr:title>Proliferating resident microglia after focal cerebral ischaemia in mice.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/841e09ddfb965c1f148f94d852b8403c"><gtr:id>841e09ddfb965c1f148f94d852b8403c</gtr:id><gtr:otherNames>Denes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>11B72789619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6478653-8C10-47AC-BA7A-DF7FE313CF9F</gtr:id><gtr:title>Leptin induces interleukin-1beta release from rat microglial cells through a caspase 1 independent mechanism.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29b44fdbc2a054a40f23794e3eeb5731"><gtr:id>29b44fdbc2a054a40f23794e3eeb5731</gtr:id><gtr:otherNames>Pinteaux E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>B36D28E0975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F56EEDB-9715-4A4F-80F3-F5FE01FA83E0</gtr:id><gtr:title>Interleukin-1 and inflammatory neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64c4d1351cb69b102ad380110e289850"><gtr:id>64c4d1351cb69b102ad380110e289850</gtr:id><gtr:otherNames>Simi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>9E8141E1D81</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FB0FD79-3258-47F9-8C7C-6CC88B2B54F8</gtr:id><gtr:title>Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation.</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29b44fdbc2a054a40f23794e3eeb5731"><gtr:id>29b44fdbc2a054a40f23794e3eeb5731</gtr:id><gtr:otherNames>Pinteaux E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn><gtr:outcomeId>D16C3A2730B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BDBCE82-C8B5-4F9E-834D-5725320AAE9E</gtr:id><gtr:title>Inflammatory responses in the rat brain in response to different methods of intra-cerebral administration.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c8d70bd8f862a34d4fcd1fdb1ea1633"><gtr:id>5c8d70bd8f862a34d4fcd1fdb1ea1633</gtr:id><gtr:otherNames>McCluskey L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>E03FCF9C5CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F208D48D-417B-4421-984B-E96D7BEE5B82</gtr:id><gtr:title>Pannexin-1-dependent caspase-1 activation and secretion of IL-1beta is regulated by zinc.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf81e6d63529589fdd81830434dc6748"><gtr:id>cf81e6d63529589fdd81830434dc6748</gtr:id><gtr:otherNames>Brough D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>35D70EE1180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1792A0DE-1A33-4D55-8109-D5EC7EECE1B1</gtr:id><gtr:title>Interleukin-1 exacerbates focal cerebral ischemia and reduces ischemic brain temperature in the rat.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f14904fc5e4f067f329560931b39cd9"><gtr:id>0f14904fc5e4f067f329560931b39cd9</gtr:id><gtr:otherNames>Parry-Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>530CD732333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDC3F285-67AA-4A3A-9859-67FCB3F7B7D3</gtr:id><gtr:title>Interleukin-1 and neuronal injury.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/445ff8e2fedbbf040520809ba9e41560"><gtr:id>445ff8e2fedbbf040520809ba9e41560</gtr:id><gtr:otherNames>Allan SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>2E625415D6B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48CDA706-1A5F-4ABB-B5AF-6C9C7C577F0C</gtr:id><gtr:title>Differential actions of IL-1 alpha and IL-1 beta in glial cells share common IL-1 signalling pathways.</gtr:title><gtr:parentPublicationTitle>Neuroreport</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0959-4965</gtr:issn><gtr:outcomeId>9F88AA4BBE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40A5E932-9E22-497B-8AD3-73590C3D4CE5</gtr:id><gtr:title>Adhesion to fibronectin regulates interleukin-1 beta expression in microglial cells.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a48ed91020521b8348a360d0bb784aff"><gtr:id>a48ed91020521b8348a360d0bb784aff</gtr:id><gtr:otherNames>Summers L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>2C6CD193B2E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95E9871C-0C1E-4F8A-9A69-E9119B6D0872</gtr:id><gtr:title>Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia.</gtr:title><gtr:parentPublicationTitle>Glia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29b44fdbc2a054a40f23794e3eeb5731"><gtr:id>29b44fdbc2a054a40f23794e3eeb5731</gtr:id><gtr:otherNames>Pinteaux E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0894-1491</gtr:issn><gtr:outcomeId>353BE385644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6029B6F8-96E2-4747-B75B-35733C78D69A</gtr:id><gtr:title>A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c1cc654a8ed34078aaa629fde95d795"><gtr:id>5c1cc654a8ed34078aaa629fde95d795</gtr:id><gtr:otherNames>Chapman KZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>AEA7EBFC782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B196EF8-9AB0-47C0-A9AE-036B4244E010</gtr:id><gtr:title>Adhesion to the extracellular matrix is required for interleukin-1 beta actions leading to reactive phenotype in rat astrocytes.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a48ed91020521b8348a360d0bb784aff"><gtr:id>a48ed91020521b8348a360d0bb784aff</gtr:id><gtr:otherNames>Summers L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>dZfKzZQp8MQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6216992-CA89-443B-BBD6-8A9B2884BE4B</gtr:id><gtr:title>Transport of interleukin-1 across cerebromicrovascular endothelial cells.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a6fd9f7b40f2de06bb6119e9738c1ed"><gtr:id>9a6fd9f7b40f2de06bb6119e9738c1ed</gtr:id><gtr:otherNames>Skinner RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>B6AE58B6870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9065E646-4FE1-4A2E-972C-298E3859EC58</gtr:id><gtr:title>Neuronal injury induces the release of pro-interleukin-1beta from activated microglia in vitro.</gtr:title><gtr:parentPublicationTitle>Brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d744b37eab5d54815ab8dca6c36aae5"><gtr:id>5d744b37eab5d54815ab8dca6c36aae5</gtr:id><gtr:otherNames>Wang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8993</gtr:issn><gtr:outcomeId>CFF7752A571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3200BC88-D055-4508-89D6-12AB954E1BD4</gtr:id><gtr:title>Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/841e09ddfb965c1f148f94d852b8403c"><gtr:id>841e09ddfb965c1f148f94d852b8403c</gtr:id><gtr:otherNames>Denes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>8FE3B72497D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F2FE508-25D3-4192-B5B8-C1563926F141</gtr:id><gtr:title>Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd02fd254ff5c1ab0efc233b3f8f0b5"><gtr:id>3dd02fd254ff5c1ab0efc233b3f8f0b5</gtr:id><gtr:otherNames>Thornton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>1E0F7778327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF46CF59-CB40-4654-BE15-7B1A3D01E2C2</gtr:id><gtr:title>The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1beta signalling responses.</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d744b37eab5d54815ab8dca6c36aae5"><gtr:id>5d744b37eab5d54815ab8dca6c36aae5</gtr:id><gtr:otherNames>Wang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn><gtr:outcomeId>39136E287FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E174282E-FF03-4FEF-8638-5F2F6671F115</gtr:id><gtr:title>The dynamics and mechanisms of interleukin-1alpha and beta nuclear import.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9d37cf5553ced351d10ac42672be61e"><gtr:id>f9d37cf5553ced351d10ac42672be61e</gtr:id><gtr:otherNames>Luheshi NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>22A93673DE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7A0066E-3E9A-436E-A9BC-68C6A8DFC712</gtr:id><gtr:title>Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokine synthesis in neurones.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68cc163b0e277ff02cf83c2295e12896"><gtr:id>68cc163b0e277ff02cf83c2295e12896</gtr:id><gtr:otherNames>Tsakiri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>65C1B9B21C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>514B4444-2094-461B-A7A1-D13000E95569</gtr:id><gtr:title>Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc8b59497dd14c62cdccb16ae234ae4"><gtr:id>ebc8b59497dd14c62cdccb16ae234ae4</gtr:id><gtr:otherNames>Patel HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn><gtr:outcomeId>178105737C7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E781EBDE-1519-4294-8FEF-4532A0BA2BE9</gtr:id><gtr:title>ADAMTS-9 expression is up-regulated following transient middle cerebral artery occlusion (tMCAo) in the rat.</gtr:title><gtr:parentPublicationTitle>Neuroscience letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5994ce7b5209b440e66c79cae622a74d"><gtr:id>5994ce7b5209b440e66c79cae622a74d</gtr:id><gtr:otherNames>Reid MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0304-3940</gtr:issn><gtr:outcomeId>Mg2bnzVqCM9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03F1539E-B823-4533-BD4F-03475AE73289</gtr:id><gtr:title>A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b90fcb86f8ff0ef88ec4421190f7ff22"><gtr:id>b90fcb86f8ff0ef88ec4421190f7ff22</gtr:id><gtr:otherNames>Ross J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>340C71FA7FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AAE4E8D-74C9-4BB8-B77C-F50E7D25FA19</gtr:id><gtr:title>KCC3 and KCC4 expression in rat adult forebrain.</gtr:title><gtr:parentPublicationTitle>Brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0a881413b7bb26fe3e7b7846d605f1a"><gtr:id>d0a881413b7bb26fe3e7b7846d605f1a</gtr:id><gtr:otherNames>Le Rouzic P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8993</gtr:issn><gtr:outcomeId>D5C0EA44D7B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12A0B3CA-FAC7-4376-9DB4-F753E74E6503</gtr:id><gtr:title>Systemic infection, inflammation and acute ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0d4d12abc03bd5e0f519c227b34e49"><gtr:id>ec0d4d12abc03bd5e0f519c227b34e49</gtr:id><gtr:otherNames>McColl BW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>73A358BE3C7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E953FD56-E8D0-4649-AF33-4CFF94E6B61C</gtr:id><gtr:title>Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [&amp;sup1;8F]-IL1RA and PET imaging in rats.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f466dc8e256d603f888c16a293004e3"><gtr:id>2f466dc8e256d603f888c16a293004e3</gtr:id><gtr:otherNames>Cawthorne C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>LvH3oBx5zGX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A48627F0-5AE5-4EB2-B5BF-394AFE5A4F73</gtr:id><gtr:title>Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0d4d12abc03bd5e0f519c227b34e49"><gtr:id>ec0d4d12abc03bd5e0f519c227b34e49</gtr:id><gtr:otherNames>McColl BW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>2C45C4527F8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69FB9331-462F-4721-9A41-65F47F1284D6</gtr:id><gtr:title>Systemic inflammation and stroke: aetiology, pathology and targets for therapy.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0d4d12abc03bd5e0f519c227b34e49"><gtr:id>ec0d4d12abc03bd5e0f519c227b34e49</gtr:id><gtr:otherNames>McColl BW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>192EE860D29</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6860F04-8270-4151-91FA-4F9B58A2C032</gtr:id><gtr:title>Interleukin-1-induced interleukin-6 synthesis is mediated by the neutral sphingomyelinase/Src kinase pathway in neurones.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68cc163b0e277ff02cf83c2295e12896"><gtr:id>68cc163b0e277ff02cf83c2295e12896</gtr:id><gtr:otherNames>Tsakiri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>DED4C5A7667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12C8EC33-9CAD-4F45-90C4-F911B80BEC76</gtr:id><gtr:title>Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0d4d12abc03bd5e0f519c227b34e49"><gtr:id>ec0d4d12abc03bd5e0f519c227b34e49</gtr:id><gtr:otherNames>McColl BW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>3FB38B79E38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FEAAF65-C31E-43E6-B8C7-5D8A4950B653</gtr:id><gtr:title>Mechanisms of interleukin-6 synthesis and release induced by interleukin-1 and cell depolarisation in neurones.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68cc163b0e277ff02cf83c2295e12896"><gtr:id>68cc163b0e277ff02cf83c2295e12896</gtr:id><gtr:otherNames>Tsakiri N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>B50F2074155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EDBE1C9-37C7-49E5-B554-972550F3B05A</gtr:id><gtr:title>Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0d4d12abc03bd5e0f519c227b34e49"><gtr:id>ec0d4d12abc03bd5e0f519c227b34e49</gtr:id><gtr:otherNames>McColl BW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>BF3A60288A1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45F43CA8-BBF7-440A-9C4E-B665311FA8F6</gtr:id><gtr:title>Mechanisms of regulation for interleukin-1beta in neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64c4d1351cb69b102ad380110e289850"><gtr:id>64c4d1351cb69b102ad380110e289850</gtr:id><gtr:otherNames>Simi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>BC37A55261C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68ACE2E8-BB7C-43A4-885A-30F8F8E34924</gtr:id><gtr:title>Regulation of expression of the novel IL-1 receptor family members in the mouse brain.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>6B854474DFE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>112A6651-2FF7-4EA6-9EA5-A8131ECFC846</gtr:id><gtr:title>The neurovascular unit and the key role of astrocytes in the regulation of cerebral blood flow.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a7217e39026d861ec3d09d165e34c17"><gtr:id>0a7217e39026d861ec3d09d165e34c17</gtr:id><gtr:otherNames>Allan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>A67F20C9A53</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9219675</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>